When it comes to the clinical-stage immunotherapy company discussed in today’s article, the author notes that “Despite being years away from making the jump from clinical to a commercial stage company, there have been numerous instances in the past several years of the stock seeing 100% or greater returns over periods of three months or less.” Given this, and with…
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s article of the five stocks he highlights, all of which are smaller-cap tech companies trading under the $10 level. For these five tech stocks, CLICK HERE.
Of the biotech industry, the author of today’s article notes that it “has seen its share of losses over the past couple of months but that provides us the perfect opportunity to pick up shares of stocks that could see substantial gains in the months ahead.” With that, he proceeds to highlight three undervalued biotech stocks poised to see their…
There’s perhaps no greater catalyst for shares of a biotech company than FDA approval of one of its product candidates. Conversely, an unfavorable ruling by the FDA can send shares of a biotech firm plummeting. With the FDA having approved 40 novel drugs so far this year (compared to 27 by this same time last year), today’s article takes a…
“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count,” notes the author of today’s article. He proceeds to highlight five low-priced biotech and medtech stocks with significant upside potential to consider for very aggressive accounts. For these five stocks – including a…
After being awarded $1.6 billion in funding by the U.S. government as part of its fast-track COVID-19 vaccine program Operation Warp Speed – the largest deal made by the program – shares of Novavax surged 32% in one trading session. On the heels of this surge, do shares of Novavax have more room to run – or is there little…
With their shares having surged by more than 484%, 500% and 275%, respectively, the three stocks highlighted in today’s article are three of the best-performing pharmaceutical stocks over the past year – and despite them having already experienced monster moves higher, it may not be too late to get in on these stocks’ gains. For more on these three pharmaceutical…
When it comes to investors piling into small-cap companies that are developing potential treatments or vaccines for COVID-19 – and causing shares of those companies to take off – Europe is no different than the U.S., with some small-cap biotech names in Europe having seen four-fold gains. Today’s article looks at a number of those companies – and whether investors…
Morgan Stanley’s chief US equity strategist believes that stocks hit their true bottom on March 23rd – and that the current rally could well lead to a true recovery. To prepare for the next bull run, he’s advising clients to buy into small-cap stocks, so today’s article highlights “three micro-cap penny stock companies with super-low entry costs (a dollar per…
“Instead of worrying about how far share prices will fall or how widely the coronavirus will spread, think about the opportunities,” advises the author of today’s article, who proceeds to outline four opportunities he sees currently – including an opportunity for retirees who need cash from their homes. For more, CLICK HERE